AMPE - NetworkNewsBreaks - Ampio Pharmaceuticals Inc. (NYSE American: AMPE) Featured in ROTH Equity Research Report
Ampio Pharmaceuticals Inc. (NYSE American: AMPE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “AMPE continues to swiftly enroll patients into its AP-013 confirmatory Phase 3 trial in severe osteoarthritis of the knee (OAK KL4), which is determining the clinical effect of Ampion on pain and function at 12 weeks in this debilitating indication. As of February 14, 875 patients were enrolled out of a minimum required 1,034, and more than 600 patients have reached the trial's 12-week primary endpoint (>58% completed), setting up for data release in 3Q20.”
To request access to the full report, visit http://nnw.fm/DXCr3
About COMPANYNAME
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2032 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act ("BPCIA").
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.